Cover Image
市場調查報告書

肺囊蟲肺炎:開發中產品分析

Pneumocystis Infection - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 321918
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
肺囊蟲肺炎:開發中產品分析 Pneumocystis Infection - Pipeline Review, H1 2016
出版日期: 2016年04月30日 內容資訊: 英文 31 Pages
簡介

肺囊蟲是生活在許多人肺部的小真菌。症狀有發熱、乾咳、呼吸急促、疲勞等。致病原因有免疫力低落(HIV),抽煙等。

本報告提供肺囊蟲肺炎的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

肺囊蟲肺炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • BioDiem Ltd.

治療藥的評估

  • 單獨療法的情況
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BDM-I
  • Monoclonal Antibody for Pneumocystis Infection
  • MVX-504
  • MVX-505
  • pneumocystis vaccine

開發中產品的最新趨勢

開發中止的產品

產品開發的里程碑

  • 熱門新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7922IDB

Summary

Global Markets Direct's, 'Pneumocystis Infection - Pipeline Review, H1 2016', provides an overview of the Pneumocystis Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pneumocystis Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pneumocystis Infection and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pneumocystis Infection
  • The report reviews pipeline therapeutics for Pneumocystis Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pneumocystis Infection therapeutics and enlists all their major and minor projects
  • The report assesses Pneumocystis Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pneumocystis Infection

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pneumocystis Infection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pneumocystis Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pneumocystis Infection Overview
  • Therapeutics Development
    • Pipeline Products for Pneumocystis Infection - Overview
    • Pipeline Products for Pneumocystis Infection - Comparative Analysis
  • Pneumocystis Infection - Therapeutics under Development by Companies
  • Pneumocystis Infection - Therapeutics under Investigation by Universities/Institutes
  • Pneumocystis Infection - Pipeline Products Glance
    • Early Stage Products
  • Pneumocystis Infection - Products under Development by Companies
  • Pneumocystis Infection - Products under Investigation by Universities/Institutes
  • Pneumocystis Infection - Companies Involved in Therapeutics Development
    • BioDiem Ltd
    • Matinas BioPharma Holdings, Inc.
  • Pneumocystis Infection - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • atovaquone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumocystis pneumonia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pneumocystis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Fungal Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pneumocystis Infection - Recent Pipeline Updates
  • Pneumocystis Infection - Dormant Projects
  • Pneumocystis Infection - Discontinued Products
  • Pneumocystis Infection - Product Development Milestones
    • Featured News & Press Releases
      • May 10, 2013: BioDiem's BDM-I Progresses To Preclinical Animal Studies In NIH Research Program As Fungal Infection Treatment
      • Jun 04, 2012: MiniVax's Pneumocystis Vaccine Candidate Induces Significant anti-Pneumocystis Antibody Responses and Reduced Fungal Load
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pneumocystis Infection, H1 2016
  • Number of Products under Development for Pneumocystis Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Pneumocystis Infection - Pipeline by BioDiem Ltd, H1 2016
  • Pneumocystis Infection - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pneumocystis Infection Therapeutics - Recent Pipeline Updates, H1 2016
  • Pneumocystis Infection - Dormant Projects, H1 2016
  • Pneumocystis Infection - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Pneumocystis Infection - Comparative Analysis, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products by Molecule Types, H1 2016
Back to Top